Vasomotor Menopausal Symptoms (VMS) Treatment Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

How Large Will the Vasomotor Menopausal Symptoms (VMS) Treatment Market Size By 2025?
The market size for treating vasomotor menopausal symptoms (VMS) has shown robust growth in the recent past. The size is forecasted to expand from $17.86 billion in 2024 to $19.19 billion in 2025, witnessing a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period is due to factors such as hormone replacement therapy (hrt), awareness of menopause, advancements in pharmaceuticals, and consumer demand.

How Big Is the Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Expected to Grow by 2029?
Predictions indicate a robust expansion in the vasomotor menopausal symptoms (VMS) treatment market size in the upcoming years. The market is projected to reach $24.81 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth in the forecast period can be linked to factors such as personalized treatments, innovation in non-hormonal treatments, nutritional and dietary changes, along with the rise of telemedicine and digital health. Major forthcoming trends comprise natural and alternative methods, the use of botanical and herbal solutions, establishment of menopause support groups, and the implementation of cognitive behavioral therapy (CBT).

View the full report here:
https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Which Key Market Drivers Powering Vasomotor Menopausal Symptoms (VMS) Treatment Market Expansion and Growth?
The upward trend in the menopausal population is anticipated to fuel the expansion of the vasomotor menopausal symptom treatment market. Menopause, a customary biological transition that signifies the conclusion of a woman's fertile years, is a significant life phase typically taking place between the ages of 45 and 55, with the median age being 51. The growing population of women experiencing menopause globally, requiring treatment for symptoms like hot flashes and vaginal dryness, represents one of the primary contributors to the vasomotor menopausal symptoms (VMS) treatment sector's expansion. For example, Cuyuna Regional Medical Center, a US-based entity, projected in November 2022 that by 2025, around 1.1 billion women would reach menopause due to extended lifespans. Furthermore, it is predicted that the population of menopausal women will rise by 1.6% annually until 2060. Hence, the surge in the menopause population steers the growth of the market for vasomotor menopausal symptom treatment. Government-driven initiatives focusing on female health during menopause are projected to further stimulate the expansion of the vasomotor menopausal symptom treatment market. These initiatives contemplate funding innovative research on menopausal transition, disease prevention, and investigation into pharmacological, clinical, and epidemiological facets. These initiatives are part of larger, inclusive efforts to improve women's health. For instance, in January 2023, the Government of New South Wales, an Australian government agency, pledged $40.3 million over a span of four years (2022-2023 to 2025-2026) to develop up to 16 new programs for women struggling with severe menopausal symptoms. Therefore, these governmental efforts targeting women's health during menopause are propelling the growth of the market for vasomotor menopausal symptoms treatment.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Leading corporations in the market for vasomotor menopausal symptoms treatment are churning out products such as Veozah and obtaining approvals to provide fresh treatment alternatives and serve patients' unmet medical needs. The green light for new menopause drugs enhances safety and efficiency compared to prevailing treatments. For instance, Astellas Pharma Inc, a pharmaceutical corporation based in Japan, got the go-ahead from the US-based federal agency FDA for their product Veozah (fezolinetant) 45 mg once daily, in May 2023. This product is aimed at treating menopausal vasomotor symptoms (VMS) ranging from mild to severe. It stands as the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved for menopausal VMS management. It's an option free of hormones that interferes with a brain pathway that regulates these symptoms. It provides a different treatment path for women affected by these symptoms, especially those who can't use or prefer to avoid hormone therapy. Veozah's approval underscored its potential as a novel drug for managing menopausal symptoms.

What Are the Emerging Segments in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented -

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

Who Are the Global Leaders in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Which are the Top Profitable Regional Markets for the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.